Genmab A/S ADR (GMAB) Social Stream
GENMAB A (GMAB) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering GENMAB A.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-11 | 6 | $50 | $37 | $44.8 | $31.75 | 41.1% |
| 2021-11-15 | 7 | $50 | $37 | $44.7 | $31.75 | 40.79% |
| 2022-01-18 | 8 | $50 | $37 | $44.7 | $31.75 | 40.79% |
| 2022-01-31 | 8 | $50 | $37 | $44.7 | $31.75 | 40.79% |
| 2022-02-28 | 8 | $50 | $37 | $42.2 | $31.75 | 32.91% |
| 2022-04-07 | 8 | $50 | $33 | $41.4 | $31.75 | 30.39% |
| 2022-04-11 | 9 | $50 | $33 | $41.416 | $31.75 | 30.44% |
| 2022-04-21 | 10 | $50 | $30 | $40.916 | $31.75 | 28.87% |
| 2022-05-02 | 10 | $50 | $30 | $40.5 | $31.75 | 27.56% |
| 2022-05-12 | 10 | $50 | $30 | $38.571 | $31.75 | 21.48% |
| 2022-05-13 | 10 | $50 | $30 | $37.9 | $31.75 | 19.37% |
| 2022-06-05 | 10 | $50 | $29 | $37.757 | $31.75 | 18.92% |
| 2022-07-20 | 11 | $53 | $29 | $38.003 | $31.75 | 19.69% |
| 2022-08-13 | 11 | $53 | $29 | $38.441 | $31.75 | 21.07% |
| 2022-08-15 | 11 | $53 | $31 | $38.691 | $31.75 | 21.86% |
| 2022-08-25 | 11 | $53 | $31 | $38.941 | $31.75 | 22.65% |
| 2022-10-19 | 11 | $53 | $31 | $39.316 | $31.75 | 23.83% |
| 2022-11-10 | 12 | $53 | $31 | $39.753 | $31.75 | 25.21% |
| 2022-11-14 | 12 | $53 | $33 | $40.128 | $31.75 | 26.39% |
| 2022-12-03 | 13 | $53 | $33 | $40.753 | $31.75 | 28.36% |
| 2023-01-03 | 13 | $53 | $33 | $42.091 | $31.75 | 32.57% |
| 2023-01-26 | 13 | $53 | $33 | $42.653 | $31.75 | 34.34% |
| 2023-02-22 | 13 | $53 | $34.73 | $43.028 | $31.75 | 35.52% |
| 2023-02-23 | 13 | $53 | $34.73 | $42.653 | $31.75 | 34.34% |
| 2023-02-26 | 13 | $54 | $34 | $42.653 | $31.75 | 34.34% |
| 2023-03-27 | 13 | $54 | $33 | $41.841 | $31.75 | 31.78% |
| 2023-04-20 | 13 | $54 | $33 | $41.341 | $31.75 | 30.21% |
| 2023-05-11 | 12 | $54 | $34.73 | $42.604 | $31.75 | 34.19% |
| 2023-05-16 | 11 | $54 | $33.001 | $41.716 | $31.75 | 31.39% |
| 2023-05-22 | 11 | $54 | $33.001 | $42.216 | $31.75 | 32.96% |
| 2023-05-25 | 12 | $54 | $33.001 | $42.841 | $31.75 | 34.93% |
| 2023-06-26 | 11 | $54 | $33.001 | $44.428 | $31.75 | 39.93% |
| 2023-08-03 | 12 | $54 | $33.001 | $44.428 | $31.75 | 39.93% |
| 2023-08-15 | 12 | $54 | $33 | $44.142 | $31.75 | 39.03% |
| 2023-08-24 | 13 | $54 | $33 | $44.125 | $31.75 | 38.98% |
| 2023-09-25 | 14 | $54 | $33 | $44.125 | $31.75 | 38.98% |
| 2023-10-12 | 14 | $54 | $33 | $44.25 | $31.75 | 39.37% |
| 2023-10-18 | 15 | $54 | $33 | $44.5 | $31.75 | 40.16% |
| 2023-11-08 | 14 | $54 | $32 | $43 | $31.75 | 35.43% |
| 2023-11-09 | 15 | $54 | $32 | $42 | $31.75 | 32.28% |
| 2023-11-28 | 15 | $54 | $32 | $41.166 | $31.75 | 29.66% |
| 2023-12-05 | 16 | $54 | $32 | $41.166 | $31.75 | 29.66% |
| 2023-12-12 | 16 | $54 | $32 | $41.166 | $31.75 | 29.66% |
The Trend in the Analyst Price Target
Over the past 29 weeks, GMAB's average price target has gone down $1.68.
GMAB reports an average of 18.87% for its upside potential over the past 46 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-26 | 13 | 54 | 34 | 42.653 | 37.43 | 13.95% |
| 2023-03-27 | 13 | 54 | 33 | 41.341 | 37.76 | 9.48% |
| 2023-03-27 | 13 | 54 | 33 | 41.841 | 37.76 | 10.81% |
| 2023-09-11 | 14 | 54 | 33 | 44.125 | 37.51 | 17.64% |
| 2023-11-08 | 14 | 54 | 32 | 43.222 | 31.00 | 39.43% |
GMAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.42 | 6 | 0 | 8 | 1 | 1 | 16 |
The Trend in the Broker Recommendations
GMAB's average broker recommendation rating improved by 0.01 over the prior 17 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how GENMAB A fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is higher than 3970.34% of that group.
- GMAB has a higher average analyst price target than 1311.94% of stocks in the large market cap category.
- GMAB has a higher upside potential (average analyst target price relative to current price) than 1463.27% of Pharmaceutical Products stocks.
- In terms of how GENMAB A fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -1592.95% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to GENMAB A are ELAN, RDY, and BGNE.
View All Top Stocks by Price Target
Is GMAB a Buy, Hold or Sell? See the POWR Ratings now!